Stoke Therapeutics, Inc. (STOK)
NASDAQ$9
Market Cap
$476.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
860 of 924
Rank in Industry
489 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
STOK Insider Trading Activity
STOK Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $96,483,616 | 29 | 100 |
Related Transactions
| Tulipano Stephen J | CFO | 0 | $0 | 1 | $25,102 | $-25,102 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | 0 | $0 | 5 | $521,189 | $-521,189 |
| Kaye Edward M. MD | CEO | 0 | $0 | 4 | $888,524 | $-888,524 |
| Ticho Barry | CHIEF MEDICAL OFFICER | 0 | $0 | 12 | $1.43M | $-1.43M |
| Nash Huw M. | COO & CBO | 0 | $0 | 4 | $1.64M | $-1.64M |
| Skorpios Trust | 10 percent owner | 0 | $0 | 3 | $91.98M | $-91.98M |
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the …
Insider Activity of Stoke Therapeutics, Inc.
Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $96.48M worth of Stoke Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $29.25M and sold $23.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.
List of Insider Buy and Sell Transactions, Stoke Therapeutics, Inc.
| 2024-12-23 | Sale | Skorpios Trust | 10 percent owner | 2M 3.6956% | $11.50 | $23M | -15.59% | |
| 2024-12-09 | Sale | Kaye Edward M. MD | CEO | 6,786 0.0122% | $12.99 | $88,158 | -25.00% | |
| 2024-12-09 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 2,586 0.0046% | $12.99 | $33,596 | -25.00% | |
| 2024-12-09 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 13,666 0.0256% | $13.61 | $185,978 | -25.00% | |
| 2024-12-06 | Sale | Kaye Edward M. MD | CEO | 6,170 0.0113% | $12.78 | $78,837 | -21.51% | |
| 2024-12-06 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 13,945 0.0256% | $12.78 | $178,182 | -21.51% | |
| 2024-12-06 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 9,696 0.0178% | $12.78 | $123,891 | -21.51% | |
| 2024-12-02 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.07 | $120,698 | -12.51% | |
| 2024-11-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.68 | $126,803 | -13.80% | |
| 2024-10-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.06 | $120,648 | -7.60% | |
| 2024-09-19 | Sale | Skorpios Trust | 10 percent owner | 1.94M 3.4152% | $14.05 | $27.22M | -23.32% | |
| 2024-09-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $14.95 | $149,481 | -21.42% | |
| 2024-08-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.019% | $14.58 | $145,843 | -17.80% | |
| 2024-07-02 | Sale | Nash Huw M. | Chief Business Officer | 2,500 0.0049% | $13.11 | $32,779 | -3.62% | |
| 2024-07-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0204% | $13.75 | $137,458 | -10.81% | |
| 2024-06-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $15.22 | $152,185 | -17.83% | |
| 2024-05-20 | Sale | Kaye Edward M. MD | CEO | 42,350 0.0779% | $15.43 | $653,529 | -20.31% | |
| 2024-05-20 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 8,599 0.0154% | $15.04 | $129,327 | -20.31% | |
| 2024-05-20 | Sale | Nash Huw M. | COO & CBO | 50,000 0.0917% | $15.39 | $769,500 | -20.31% | |
| 2024-05-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $11.37 | $113,653 | +10.55% |
Total: 104
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Harrison Seth Loring | 17161713 32.4008% | $154.46M | 2 | 0 | <0.0001% | |
| Apple Tree Partners IV, L.P. | 10 percent owner | 17161713 32.4008% | $154.46M | 2 | 0 | <0.0001% |
| RTW INVESTMENTS, LP | 10 percent owner | 3544248 6.6914% | $31.9M | 6 | 1 | <0.0001% |
Historical Insider Profitability vs. Competitors
$587,109,125 | 90 | 3.17% | $521.31M | |
$14,527,743 | 76 | 38.40% | $482.25M | |
$24,384,691 | 42 | -30.27% | $459.77M | |
$6,280,187 | 19 | 6.80% | $493.08M | |
$100,566,697 | 18 | -5.10% | $455.67M |
STOK Institutional Investors: Active Positions
| Increased Positions | 68 | +49.64% | 9M | +14.99% |
| Decreased Positions | 58 | -42.34% | 6M | -9.92% |
| New Positions | 29 | New | 7M | New |
| Sold Out Positions | 17 | Sold Out | 257,411 | Sold Out |
| Total Postitions | 147 | +7.3% | 61M | +5.07% |
STOK Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Skorpios Trust | $59,393.00 | 13.03% | 6.91M | -2M | -22.46% | 2024-12-31 |
| Blackrock, Inc. | $50,633.00 | 11.11% | 5.89M | +317,361 | +5.7% | 2024-12-31 |
| Lynx1 Capital Management Lp | $44,610.00 | 9.79% | 5.19M | 0 | 0% | 2024-12-31 |
| Rtw Investments, Lp | $44,062.00 | 9.67% | 5.12M | +471,240 | +10.13% | 2024-12-31 |
| Baker Bros. Advisors Lp | $39,851.00 | 8.74% | 4.63M | +265,395 | +6.08% | 2024-12-31 |
| Redmile Group, Llc | $39,505.00 | 8.67% | 4.59M | -119,880 | -2.54% | 2024-12-31 |
| Morgan Stanley | $29,560.00 | 6.49% | 3.44M | -768,063 | -18.26% | 2024-12-31 |
| Cowen And Company, Llc | $27,903.00 | 6.12% | 3.24M | -121,246 | -3.6% | 2024-09-30 |
| Toronto Dominion Bank | $27,290.00 | 5.99% | 3.17M | +3M | New | 2024-12-31 |
| Vanguard Group Inc | $23,488.00 | 5.15% | 2.73M | -28,049 | -1.02% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.